Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Pancreatic Neoplasms 1Multiple Myeloma 1Burkitt Lymphoma 1Adenocarcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 6Radiotherapy, Intensity-Modulated 5Cisplatin 5Carboplatin 5Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4artesunic acid 3artemisinin 3Paclitaxel 3Human Papillomavirus Recombinant Vaccine nonavalent 3artenimol 2Vaccines, Synthetic 2Taxes 2Radiation 2Imiquimod 2GX-188 vaccine 2Docetaxel 2Albumin-Bound Paclitaxel 2utomilumab 1toripalimab 1polyphenon E 1infigratinib 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1aldesleukin 1Viusid 1Vaccines 1VP-102 1Therapies, Investigational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Papillomavirus Infections × Biological Products × Clear all
NCT04436133 2022-05-06

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

National Vaccine and Serum Institute, China

Phase 2 Completed
480 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡